Case study: Cannabis might dampen the pain, but amplify the psychosis!

FHS
May 7, 2024
4:27 am

Case study details a 27-year-old woman with schizoaffective disorder and fibromyalgia who used high-potency cannabis to alleviate pain but experienced adverse psychiatric effects. A month-long diet lowering free glutamate improved her pain, mental health, and allowed her to quit cannabis, highlighting the risks of cannabis self-medication for pain management.

EASD 2024: Novo Nordisk’s Saxenda shows weight loss in children

Saxenda was approved by the US Food and Drug Administration (FDA) for obesity management for adolescents aged 12 years and older, in 2020. Image credit:

September 11, 2024

Analysis suggests the need for pharma research into non-motor symptoms of Parkinson’s disease

Analysis of the online conversations among patients with Parkinson’s Disease suggests a need for pharmaceutical research to be targeted at treating the non-motor symptoms of

October 12, 2023

Understanding astrocyte-neuron interplay in learning deficits

In the brain, synaptic plasticity – the ability to change neuronal connections over time – is fundamental to learning and memory.

July 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.